LOSARTAN AS AN ENHANCER OF MYSCLE TISSUE PERFUSION IN ELDERLY: A PILOT

氯沙坦作为老年人肌组织灌注增强剂：试点

• 批准号: 7952165
• 负责人: Melinda Sheffield-Moore
• 金额: $ 0.67万
• 依托单位: UNIVERSITY OF TEXAS MED BR GALVESTON
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7952165
• 关键词: Amino Acids; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Data; Elderly; Enhancers; FDA approved; Funding; Goals; Grant; Institution; Losartan; Measures; Muscle; Nutrient; Perfusion; Pilot Projects; Renin-Angiotensin-Aldosterone System; Research; Research Personnel; Resources; Source; Tissues; Ultrasonography; United States National Institutes of Health; Vasodilator Agents; Woman; inhibitor/antagonist; older men

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this pilot study is to determine whether Losartan, an FDA approved vasodilator, enhances muscle tissue perfusion in older men and women. Data from this pilot study will be used as preliminary data for resubmission of Dr. Sheffield-Moore's NIH/NIA R01 Competitive renewal. We hypothesize that Losartan, a common vasodilator, can enhance muscle tissue perfusion in the elderly. The goal of this pilot project is to determine whether Losartan, an FDA approved vasodilator and an inhibitor of the renin-angiotensin-aldosterone system, can acutely stimulate muscle tissue perfusion in elderly (as measured with contrast enhanced ultrasound). Subjects will be administered 50mg of Losartan with Doppler and CEU to follow. Results from this pilot study will go a long way to convince reviewers that Losartan is capable of enhancing muscle tissue perfusion, and thus facilitating the nutritive exchange of nutrients such as amino acids.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这项试点研究的目的是确定洛沙坦（FDA 批准的血管扩张剂）是否可以增强老年男性和女性的肌肉组织灌注。该试点研究的数据将用作重新提交 Sheffield-Moore 博士的 NIH/NIA R01 竞争性更新的初步数据。 我们假设氯沙坦是一种常见的血管扩张剂，可以增强老年人的肌肉组织灌注。 该试点项目的目标是确定氯沙坦（FDA 批准的血管舒张剂和肾素-血管紧张素-醛固酮系统抑制剂）是否可以急性刺激老年人的肌肉组织灌注（通过对比增强超声测量）。 受试者将接受 50 毫克氯沙坦治疗，随后使用多普勒和 CEU。 这项试点研究的结果将在很大程度上让审稿人相信氯沙坦能够增强肌肉组织灌注，从而促进氨基酸等营养物质的营养交换。